Gene therapy patients tracked for 15 years to uncover hidden risks
NCT ID NCT05713214
First seen Jun 06, 2026 · Last updated Jun 20, 2026 · Updated 5 times
Summary
This study follows 500 patients who have received genetically modified cell therapies at St. Jude Children's Research Hospital. The goal is to monitor for any delayed side effects or medical events over 15 years. Participants will have regular check-ins to track their health. This is not a treatment study, but it helps ensure the long-term safety of these advanced therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED HEMATOLOGIC MALIGNANCY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
St. Jude Children's Research Hospital
RECRUITINGMemphis, Tennessee, 38105, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
genetically modified cell products
What this could lead to
If successful, this study will provide crucial safety data on gene-modified cell therapies, helping to make them safer for future patients.
What could go wrong
This is a long-term observational follow-up, not a treatment trial. It does not test a new therapy, so there is no direct benefit to participants. The main risk is the inconvenience of follow-up visits.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.